Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

For 2025, Regeneron reiterated its projection for research-and-development spending in a range between $5.56 billion and $5.795 billion. The company cut the top end of its forecasted range for 2025 ...

The S&P 500 advanced 0.6% on Tuesday, April 29, notching a sixth straight winning session. The White House signaled it would ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...